{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:56:50Z","timestamp":1773320210907,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,11]]},"DOI":"10.7759\/cureus.105055","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:18:16Z","timestamp":1773256696000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Risankizumab in Moderate to Severe Psoriasis Considering Body Mass Index: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Karina","family":"Sarmiento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Siqueiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximiliano","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F","family":"Pumarejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo D","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.097","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry","volume":"90","author":"Strober B","year":"2024","unstructured":"Strober B, Ferris L, Callis Duffin K, et al.. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024, 90:82-90. 10.1016\/j.jaad.2023.08.097","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59112006","article-title":"An observational study of 147 psoriasis patients: overweightness and obesity as significant clinical factors correlated with psoriasis","volume":"59","author":"Czarnecka A","year":"2023","unstructured":"Czarnecka A, Zab\u0142otna M, Purzycka-Bohdan D, Nowicki RJ, Szczerkowska-Dobosz A. An observational study of 147 psoriasis patients: overweightness and obesity as significant clinical factors correlated with psoriasis. Medicina (Kaunas). 2023, 59:2006. 10.3390\/medicina59112006","journal-title":"Medicina (Kaunas)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18010","article-title":"Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis","volume":"36","author":"Gooderham M","year":"2022","unstructured":"Gooderham M, Pinter A, Ferris LK, et al.. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022, 36:855-65. 10.1111\/jdv.18010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey H","year":"2005","unstructured":"Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005, 8:19-32. 10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac D","year":"2010","unstructured":"Levac D, Colquhoun H, O'Brien K. Scoping studies: advancing the methodology. Implement Sci. 2010, 5:69. 10.1186\/1748-5908-5-69","journal-title":"Implement Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00679-6","article-title":"Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: subgroup analysis from the IMMerge study","volume":"12","author":"Crowley JJ","year":"2022","unstructured":"Crowley JJ, Langley RG, Gordon KB, et al.. Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: subgroup analysis from the IMMerge study. Dermatol Ther (Heidelb). 2022, 12:561-75. 10.1007\/s13555-021-00679-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober B","year":"2020","unstructured":"Strober B, Menter A, Leonardi C, et al.. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020, 34:2830-8. 10.1111\/jdv.16521","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041675","article-title":"Risankizumab therapy for moderate-to-severe psoriasis - a multi-center, long-term, real-life study from Poland","volume":"12","author":"Adamczyk M","year":"2023","unstructured":"Adamczyk M, Bartosi\u0144ska J, Raczkiewicz D, et al.. Risankizumab therapy for moderate-to-severe psoriasis - a multi-center, long-term, real-life study from Poland. J Clin Med. 2023, 12:1675. 10.3390\/jcm12041675","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01238-5","article-title":"Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials","volume":"14","author":"Gordon KB","year":"2024","unstructured":"Gordon KB, Blauvelt A, Bachelez H, et al.. Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials. Dermatol Ther (Heidelb). 2024, 14:2523-38. 10.1007\/s13555-024-01238-5","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2024.02.030","article-title":"Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study","volume":"116","author":"Martorell-Calatayud A","year":"2025","unstructured":"Martorell-Calatayud A, Santos-Alarc\u00f3n S, Sahuquillo-Torralba A, et al.. Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study. Actas Dermosifiliogr. 2025, 116:125-33. 10.1016\/j.ad.2024.02.030","journal-title":"Actas Dermosifiliogr"},{"key":"ref11","article-title":"Informe de posicionamiento terap\u00e9utico de risankizumab (Skyrizi\u00ae) en psoriasis en placas","author":"Agencia Espa\u00f1ola de Medicamentos","year":"2007","unstructured":"Agencia Espa\u00f1ola de Medicamentos. Informe de posicionamiento terap\u00e9utico de risankizumab (Skyrizi\u00ae) en psoriasis en placas. Ministerio de Sanidad, 2007."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study","volume":"101","author":"Borroni RG","year":"2021","unstructured":"Borroni RG, Malagoli P, Gargiulo L, et al.. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021, 101:adv00605. 10.2340\/actadv.v101.283","journal-title":"Acta Derm Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt A","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al.. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020, 156:649-58. 10.1001\/jamadermatol.2020.0723","journal-title":"JAMA Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093233","article-title":"Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study","volume":"12","author":"Megna M","year":"2023","unstructured":"Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023, 12:3233. 10.3390\/jcm12093233","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up","volume":"89","author":"Papp KA","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, et al.. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up. J Am Acad Dermatol. 2023, 89:1149-58. 10.1016\/j.jaad.2023.07.1024","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020495","article-title":"Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (Italian Landscape Psoriasis)","volume":"13","author":"Gargiulo L","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al.. Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (Italian Landscape Psoriasis). J Clin Med. 2024, 13:495. 10.3390\/jcm13020495","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-2631","article-title":"Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study","volume":"96","author":"Timis TL","year":"2023","unstructured":"Timis TL, Beni L, Florian IA, Or\u0103san M, Or\u0103san RI. Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study. Med Pharm Rep. 2023, 96:368-83. 10.15386\/mpr-2631","journal-title":"Med Pharm Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03419-w","article-title":"Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study","volume":"316","author":"Rompoti N","year":"2024","unstructured":"Rompoti N, Koumprentziotis IA, Stefanaki I, et al.. Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study. Arch Dermatol Res. 2024, 316:667. 10.1007\/s00403-024-03419-w","journal-title":"Arch Dermatol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15489","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study","volume":"35","author":"Caldarola G","year":"2022","unstructured":"Caldarola G, Zangrilli A, Bernardini N, et al.. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022, 35:e15489. 10.1111\/dth.15489","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16849","article-title":"Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas","volume":"62","author":"Vaiopoulos AG","year":"2023","unstructured":"Vaiopoulos AG, Dalamaga M, Katsimbri P, et al.. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023, 62:1404-13. 10.1111\/ijd.16849","journal-title":"Int J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00795-x","article-title":"Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study","volume":"12","author":"Gargiulo L","year":"2022","unstructured":"Gargiulo L, Ibba L, Pavia G, et al.. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022, 12:2309-24. 10.1007\/s13555-022-00795-x","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2425029","article-title":"Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study","volume":"35","author":"Ibba L","year":"2024","unstructured":"Ibba L, Di Giulio S, Gargiulo L, et al.. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatolog Treat. 2024, 35:2425029. 10.1080\/09546634.2024.2425029","journal-title":"J Dermatolog Treat"},{"key":"ref23","article-title":"Risankizumab en la psoriasis moderada - grave, experiencia de una cohorte de pacientes","author":"Tejedor T","year":"2023","unstructured":"Tejedor T, Rodr\u00edguez G, Moreno L, de la Plata M, Ure\u00f1a H, Muner S. Risankizumab en la psoriasis moderada - grave, experiencia de una cohorte de pacientes. ILAPHAR. 2023,","journal-title":"ILAPHAR"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15378","article-title":"Risankizumab shows high efficacy and maintenance in improvement of response until week 52","volume":"35","author":"Mastorino L","year":"2022","unstructured":"Mastorino L, Susca S, Megna M, et al.. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022, 35:e15378. 10.1111\/dth.15378","journal-title":"Dermatol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r A","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, et al.. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022, 81:351-8. 10.1136\/annrheumdis-2021-221048","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01292-z","article-title":"Efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab: results from a phase 3b, open-label, single-arm (aIMM) study","volume":"14","author":"Warren RB","year":"2024","unstructured":"Warren RB, Pavlovsky L, Costanzo A, et al.. Efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab: results from a phase 3b, open-label, single-arm (aIMM) study. Dermatol Ther (Heidelb). 2024, 14:3273-90. 10.1007\/s13555-024-01292-z","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389356-efficacy-of-risankizumab-in-moderate-to-severe-psoriasis-considering-body-mass-index-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:18:17Z","timestamp":1773256697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389356-efficacy-of-risankizumab-in-moderate-to-severe-psoriasis-considering-body-mass-index-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.105055","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}